876.55
-7.20 (-0.81%)
ALIVUS • 08 Dec, 2025 | 09:44 AM
1Y Annualised Return
▼-9.11%
3Y Annualised Return
▲29.30%
Alivus Life Sciences Stock Performance
|
|
|
Alivus Life Sciences Company background
Founded in: 2011
Managing director: Yasir Yusufali Rawjee
Alivus Life Sciences Limited was initially established as Zorg Laboratories Private Limited, on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune. Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to Alivus Life Sciences Limited on January 20, 2025. Nirma Limited is a Subsidiary of the Company. The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business. The first product registered with USFDA in 2003. The Company acquired Glaxo SmithKlines (GSK) API manufacturing plant in Ankleshwar, Gujarat in 2003. It established manufacturing plant at Kurkumbh, Maharashtra in 2002. In 2004, it commenced manufacturing at Mohol, Maharashtra. In 2013, the Company commenced manufacturing at Dahej, Gujarat. The Company acquired API Division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January, 2019. The Company increased its API manufacturing capabilities by enhancing the existing production capacities at Ankleshwar Dahej facilities in FY 2023, by an aggregate annual total installed capacity of 640 KL.The Company expanded projects with additional 240 KL at Dahej in 2023. The brownfield expansion at Dahej for Oncology Plant was completed. Out of the 2 independent modules, one module commissioned 100%. 192 KL out of the 400 KL intermediate manufacturing block at Ankleshwar commissioned in 2023. The Company came up with an IPO of 21,022,222 Equity Shares comprising a Fresh Issue of 14,722,222 Equity Shares and Offer for Sale of 6,300,000 Equity Shares aggregating to Rs 1513.6 Crores in August, 2021.FY24 ushered in a new chapter with Nirma Limited, a diversified conglomerate with interests in consumer products, cement, chemicals, and pharmaceuticals, acquiring a majority stake in GLS. In FY 202324, 75% of the equity stake of the Company was transferred by the promoter, Glenmark Pharmaceuticals Limited (GPL) to Nirma Limited on March 6, 2024. Resulting this, there was a change in ownership status via share purchase agreement, and Nirma became the new promoter of the Company.A separate facility for Ezetimibe was commissioned and became operational at Ankleshwar in FY25. Two independent modules were commissioned in FY 2025 and made operational at Dahej.
Alivus Life Sciences Financial Highlights
As of Sep '25, Alivus Life Sciences’s market capitalisation stood at ₹10,841.96 crores.
Shareholding as of Sep '25 shows promoters holding 74.9%, with FIIs at
6.8%, DIIs at 5.5%, and public at 12.8%.
Alivus Life Sciences Share Price Today
As of 8 Dec 2025, Alivus Life Sciences share price is ₹877.4. The stock opened at ₹887 and had closed at ₹883.8 the previous day. During today’s trading session, Alivus Life Sciences share price moved between ₹875.00 and ₹887.00, with an average price for the day of ₹881.00. Over the last 52 weeks, the stock has recorded a low of ₹850.00 and a high of ₹1,251.00. In terms of performance, Alivus Life Sciences share price has declined by 12.8% over the past six months and has declined by 9.11% over the last year.
Alivus Life Sciences SIP Return Calculator
Over the past
1 year
3 years
Total Investment of ₹1,80,000
Monthly SIP of ₹5,000 would have become ₹2,90,163 in 3 years with a gain of ₹1,10,163 (+61.20%)
Alivus Life Sciences Fundamental
Market Cap (in crs)
10,841.96
Face Value
2
Turnover (in lacs)
47.81
Key Metrics
Qtr Change %
Near 52W Low of ₹850.00
-5
Dividend yield 1yr %
Below industry Median
0.6
Alivus Life Sciences Technical Analysis
Moving Averages Analysis
Moving Averages Analysis
876.55
Current Price
Day EMA5
883.50
Day EMA10
889.90
Day EMA12
892.00
Day EMA20
898.40
Day EMA26
902.30
Day EMA50
916.50
Day EMA100
943.30
Day EMA200
970.30
Day SMA5
884.20
Day SMA10
890.70
Day SMA20
902.50
Day SMA30
904.90
Day SMA50
916.40
Day SMA100
948.00
Day SMA150
983.10
Day SMA200
993.60
Delivery & Volume
| Period | Combined Delivery Volume | NSE+BSE Traded Volume |
|---|---|---|
Day Rs | 89964 Rs | 187936 Rs |
Week Rs | 436897 Rs | 621009 Rs |
Month Rs | 166007 Rs | 231892 Rs |
Resistance & Support
883.25
Pivot
Resistance
First Resistance
893.50
Second Resistance
903.25
Third Resistance
913.50
Support
First Support
873.50
Second support
863.25
Third Support
853.50
Relative Strength Index
42.68
Money Flow Index
19.17
MACD
-10.31
MACD Signal
-8.18
Average True Range
21.80
Average Directional Index
10.30
Rate of Change (21)
-0.76
Rate of Change (125)
-12.16
Alivus Life Sciences Peer comparison
Compare
| Index Name | Market Price | Market Cap | 52W Low | 52W High | Prev. Close | 1W Return | 1M Return | 6M Return | 1Y Return | 3Y Return | Dividend Yield | PE Ratio | Industry PE | PB Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1,936.30 | 14,924.14 | 1599 | 2641 | 1,963.40 | 1.42% | 0.20% | -7.50% | -17.77% | 159.30% | 0.31% | 42.68 | 41.70 | 8.09 | |
565.90 | 13,610.08 | 422 | 621.1 | 560.85 | -0.50% | 2.03% | 6.78% | -1.69% | 69.25% | 0.27% | 37.58 | 41.70 | 3.83 | |
4,293.60 | 9,972.45 | 4290 | 6717 | 4,330.20 | -1.54% | -7.40% | -30.15% | -31.22% | -24.98% | 2.70% | 27.03 | 41.70 | 12.76 | |
1,699.50 | 13,980.31 | 918.78 | 1902 | 1,707.60 | -4.19% | -3.71% | 49.01% | 52.89% | 251.73% | 0.09% | 61.94 | 41.70 | 9.87 | |
4,631.00 | 10,721.45 | 4537.45 | 5894.5 | 4,655.30 | 0.32% | -0.25% | -8.08% | -3.54% | 0.00% | 1.18% | 49.85 | 41.70 | 41.67 | |
638.00 | 10,474.82 | 570.75 | 754.8 | 635.80 | -0.34% | 1.72% | 0.00% | 0.00% | 0.00% | 0.00% | 62.20 | 41.70 | 8.94 |
Alivus Life Sciences Share Price FAQs
What is Share Price of Alivus Life Sciences ?
Alivus Life Sciences share price is ₹876.55 in NSE and ₹877.75 in BSE as on 8/12/2025.
How has Alivus Life Sciences shares performed in the past ?
Alivus Life Sciences share price in the past 1-year return was -17.03. The Alivus Life Sciences share hit a 1-year low of Rs. 850 and a 1-year high of Rs. 1251.
What is the market cap of Alivus Life Sciences ?
The market cap of Alivus Life Sciences is Rs. 10841.96 Cr. as of 8/12/2025.
What is the current P/E ratio of Alivus Life Sciences ?
The PE ratios of Alivus Life Sciences is 20.43 as of 8/12/2025.
What is the current PB ratio of Alivus Life Sciences ?
The PB ratios of Alivus Life Sciences is 3.59 as of 8/12/2025
What is the Mutual Fund shareholding in Alivus Life Sciences ?
The Mutual Fund Shareholding in Alivus Life Sciences was 3.87% at the end of 8/12/2025.
How to buy Alivus Life Sciences shares?
You can easily buy Alivus Life Sciences shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.
What is the 52-week high and low of Alivus Life Sciences ?
The 52-week high and low of Alivus Life Sciences share price is ₹1251 and ₹850 as of 8/12/2025.
Please be aware that Alivus Life Sciences stock prices are subject to continuous fluctuations due to various factors.
Invest in Alivus Life Sciences